BUSINESS
Vibegron Prescription Soars after 14-Day Limit Lifted, Triggering Shipment Curbs
Kyorin Pharmaceutical/Kissei Pharmaceutical’s overactive bladder drug Beova (vibegron) has seen demand significantly higher than expected since its 14-day prescription was lifted in December, prompting the companies to curb shipments and ask healthcare providers to restrict its use for certain patients.…
To read the full story
Related Article
- Supply Control for Beova to Last until FY2022: Kyorin/Kissei
January 29, 2021
BUSINESS
- Ono Partners with Congruence on Neurology, Immunology Drug Discovery
March 5, 2026
- Takeda Files Japan NDA for Narcolepsy Drug Oveporexton
March 5, 2026
- Nxera Files for Daridorexant Approval in South Korea
March 5, 2026
- Sawai Prevails in Patent Suit against Viatris over Amitiza Generic
March 5, 2026
- Kyowa Kirin Halts Rocatinlimab Clinical Trials on Malignancy Concerns
March 4, 2026
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…





